Our data revealed that the combination of Pingwei Pill, an NMPA-approved TCM identified as an MCR inhibitor, and colistin represents a new therapeutic strategy for bacterial infection to meet current clinical challenges. The gene discussed is NR3C2; the disease is bacterial infectious disease.